ivermectin for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID-19 mild to moderate meta-analysis
Kirti CTRI/2020/08/027225		RCT	ivermectin	placebo	COVID-19 mild to moderate	some concern	57/58	inconclusive	inconclusive 20 % decrease in viral clearance by day 7 (PE) with a moderate degree of certainty due to some concern in risk of bias
RIVET-COV (Mohan) (12mg and 24mg) CTRI/2020/06/026001		RCT	ivermectin	placebo	COVID-19 mild to moderate	high	104/52	inconclusive	inconclusive 10 % increase in viral clearance ,viral clearance by day 7 (PE) but with a low degree of certainty due to high risk of bias
Ahmed		RCT	ivermectin	placebo	COVID-19 mild to moderate	high	48/24	suggested	suggested 3.1-fold increase in viral clearance (time to event analysis only),viral clearance by day 14 (PE) but with a low degree of certainty due to high risk of bias Paradoxically comparison of day 7 and 14 virological clearance between ivermectin doxycycline group vs placebo was not statistically significant (HR 2.3[0.6-9.0] and 1.7[0.8-4.0])
Chaccour NCT04390022		RCT	ivermectin	placebo	COVID 19 outpatients, COVID-19 mild to moderate	low	12/12	inconclusive	inconclusive 8 % decrease in viral clearance ,viral clearance by day 7 (PE) with a high degree of certainty due to low risk of bias
1 study excluded by filtering options (0 RCT / 1 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID-19 mild to moderate meta-analysis